Indobufen-based dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and network meta-analysis
Objective Indobufen has been proposed as an aspirin substitute within dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), but has been compared only with aspirin plus clopidogrel. We aimed to estimate the comparative safety and efficacy of indobufen-based DAPT against contemporary antiplate...